In combination with ADAM10 and ADAM17 inhibition decreasing GSC proliferation, these new therapeutic targets may provide a mechanism for depletion of the tumourigenic stem cell pool that seeds the tumour whilst sparing native neural stem cells. Here, ADAM17 is linked to neoplasm.